更新于：2024-12-21
Magnesium valproate
丙戊酸镁
更新于：2024-12-21
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期- |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H32MgO4 |
InChIKeyAOKPYFGZNIEWKA-UHFFFAOYSA-N |
CAS号62959-43-7 |
关联
6
项与 丙戊酸镁 相关的临床试验A Randomized Clinical Trial, Double Blind, Placebo-controlled of Lithium and Valproate in Amyotrophic Lateral Sclerosis.
Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer.
Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.
100 项与 丙戊酸镁 相关的临床结果
登录后查看更多信息
100 项与 丙戊酸镁 相关的转化医学
登录后查看更多信息
100 项与 丙戊酸镁 相关的专利（医药）
登录后查看更多信息
56
项与 丙戊酸镁 相关的文献（医药）2024-05-06Revista medica del Instituto Mexicano del Seguro Social
Article
作者: Alonso-Torres, Gisela ; García-Galicia, Arturo ; Aréchiga-Santamaría, Alejandra ; Tapia-Venancio, Maricarmen ; López-García, Diana ; Bertado-Ramírez, Nancy Rosalía ; Montiel-Jarquín, Álvaro José ; Cruz-Cruz, Blanca Estela ; Martínez-Fernández, Omar Alejandro
Background:
Epilepsy affects from 0.5 to 1% of children worldwide and has a cognitive impact on the patient.
Objective:
To assess cognitive characteristics in pediatric patients diagnosed with epilepsy.
Material and methods:
Analytical, cross-sectional study of patients with epilepsy aged 6 to 16 years in a tertiary hospital in Puebla, Mexico. Type of epilepsy, evolution, treatment, and school performance were evaluated. The Wechsler Intelligence Scale IV was used for cognitive characteristics. Mann-Whitney U and phi coefficients were used. It was considered statistically significant a p < 0.05.
Results:
95 patients were included, 61.1% were male. Mean: age 11.16 years (± 2.5), school performance 7.8 (± 0.99), time of development: 2.4 years (± 1.4). They were schoolchildren aged 6-11 years (36.8%) and adolescents aged 12-16 years (63.2%); 79% had generalized epilepsy; 93.6% were treated with monotherapy (47.3% with magnesium valproate). The mean intellectual quotient was 90.3 (± 10.02), decreased in 12 patients (12.6%). Working memory was the most commonly affected domain (31.6%), mostly in adolescents with 40% (p = 0.021). Perceptual reasoning and working memory were significantly correlated with developmental time (phi = 0.17, p = 0.04 and phi = 0.49, p < 0.001, respectively).
Conclusions:
Working memory was the most affected cognitive characteristic, especially in adolescents. Working memory and perceptual reasoning were affected by time of development.
2023-09-01European journal of pharmacology
Corrigendum to “Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus” [Eur. J. Pharmacol. 728 (5 April 2014) 128–134]
作者: Raghunathan, Suchi ; Porwal, Urvashi ; Patel, Bhoomika M
2023-04-01Alternative therapies in health and medicine
Systematic Review and Meta-Analysis of Salt Valproate Preventing Switch Associated with Antidepressants in Chinese Patients With Depressive Episodes.
Review
作者: Fengli, Sun ; Lv, Wangqiang ; Dong, Shen ; Weidong, Jin
Objective:
This overview of systematic reviews (SRs) and meta-analyses aims to critically appraise the methodology and reporting quality of relevant SRs and meta-analyses with the aim of identifying whether or not the use of valproate can prevent the switch to mania associated with antidepressant treatment in Chinese patients with depressive episodes.
Methods:
Electronic databases China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP database) and Wanfang Database were searched for related SRs and meta-analyses from inception to the search date within Chinese restrictions. A total of 2 reviewers independently selected SRs and meta-analyses and collected related data, and a third reviewer was introduced if any disagreement occurred during the assessment. The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) and the US Agency for Healthcare Research and Quality (AHRQ) were employed to evaluate quality of the reporting and methodology.
Results:
The switch rate in the sodium valproate group by 99% and was significantly lower than in the antidepressant-only group (0% vs 5.7%; OR = 0.18; 95% CI, 0.04-0.84; Z = 2.18; P = .03). The magnesium valproate group was similar to the sodium valproate group in switch rate; the switch rate in the antidepressant group was (2.2% vs 16.92%; OR = 0.11; 95% CI, 0.03-0.39; Z = 3.47; P = .0005). The switch rate in the salt valproate combined with a selective serotonin reuptake inhibitor (SSRI) group was lower than in the SSRI group (0.51% vs 8.4%; OR = 0.15; 95% CI, 0.04-0.51; Z = 3.01; P = .003). The switch rate in the valproate combined with serotonin noradrenaline reuptake inhibitor (SNRI) group was similar to the valproate combined with SNRI group (2.3% vs 17.5%; OR = 0.12; 95% CI, 0.03-0.53; Z = 2.79; P = .05).
Conclusion:
Salt valproate can reduce the switch rate related to antidepressant treatment in patients with depression.
100 项与 丙戊酸镁 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 实体瘤 | 临床2期 | 墨西哥 | 2007-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 二线 | - | 製範蓋艱範網鹽糧夢膚(鑰艱鏇壓餘蓋夢膚夢選) = supply, adherence and some drug interactions that in all cases they were responsible for therapeutic failure or adverse reactions to the initial medication 願膚醖憲觸蓋鑰鏇選襯 (襯鏇願選鏇醖顧廠鏇願 ) 更多 | 积极 | 2013-06-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用